GF
HBIO icon

Gabelli Funds’s Harvard Bioscience HBIO Stock Holding History

Gabelli Funds’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,900
Closed -$26.1K – 1295
2025
Q4 		$26.1K Hold
3,900
– – ﹤0.01% 1223
2025
Q3 		$17.1K Sell
3,900
-1,100
-22% -$5.22K ﹤0.01% 1225
2025
Q2 		$22.2K Sell
5,000
-1,500
-23% -$6.27K ﹤0.01% 1196
2025
Q1 		$36.8K Hold
6,500
– – ﹤0.01% 1059
2024
Q4 		$137K Buy
6,500
+500
+8% +$11.5K ﹤0.01% 1034
2024
Q3 		$161K Buy
6,000
+1,500
+33% +$44.2K ﹤0.01% 1024
2024
Q2 		$128K Buy
+4,500
New +$158K ﹤0.01% 1019

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gabelli Funds's HBIO Position: Q1 2026 in Review

Gabelli Funds sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 3,900 shares — an estimated $26.1K sold.

Gabelli Funds first reported a position in HBIO in Q2 2024 and held it in 7 quarters. The position peaked at $161K in Q3 2024. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Gabelli Funds reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Gabelli Funds sold 3,900 Harvard Bioscience shares in Q1 2026, an estimated $26.1K.
  • Gabelli Funds first reported a position in Harvard Bioscience in Q2 2024 and held it in 7 quarters.
  • Gabelli Funds's Harvard Bioscience position peaked at $161K in Q3 2024.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Gabelli Funds's 13F filing for Q1 2026, filed 14 May 2026.